Antiretroviral abacavir linked with cardiovascular events in REPRIEVE trial
MedPage Today highlights UC-led trial analysis
People with HIV who took the antiretroviral drug abacavir (Ziagen) had an increased risk of major adverse cardiovascular events (MACE), according to an exploratory analysis of the REPRIEVE trial presented by the University of Cincinnati's Carl Fichtenbaum, MD, at the International AIDS Conference.
MedPage Today highlighted the findings that past use of abacavir increased the risk of MACE by 50% and current use increased MACE risk by 42%.
"Hopefully, with newer antiretrovirals and longer-acting therapy, perhaps this will become less and less of a problem as we're able to shift away and use other things to control HIV replication," said Fichtenbaum, professor in the Division of Infectious Diseases in the UC College of Medicine.
"Since there are many other options available — certainly in high-income countries — I think we have to consider the fact that the most important thing is controlling HIV replication, but that where we can, it may be helpful to avoid the use of abacavir," Fichtenbaum continued.
Read the MedPage Today article.
U.S. Pharmacist also highlighted the research. Read the U.S. Pharmacist article.
Featured photo at top of illustration of cardiovascular system. Photo/magicmine/iStock.
Related Stories
Recent advances may speed time to endometriosis diagnosis
March 16, 2026
The average time to clinical diagnosis of endometriosis is nine years. Definitive diagnosis of the disease is difficult, and until recently, has relied on laparoscopic surgery. Now, as Medscape recently reported, novel clinical recommendations, advanced diagnostic tools and research into inflammation and immune responses, are bringing promise that women with endometriosis will find relief sooner and without surgery, according to experts, including Katie Burns, PhD, University of Cincinnati College of Medicine associate professor.
Position-specific helmets may not improve protection
March 16, 2026
Local 12 highlighted a new study by biomedical engineering researchers that looked at how well new football helmets protected players from impacts that can cause concussions.
UC biologist talks about 'pearmageddon'
March 16, 2026
WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.